Research programme: hearing and balance loss gene therapy - GenVec/NovartisAlternative Names: Atonal gene therapy - GenVec/Novartis; Hearing loss gene therapy - GenVec/Novartis; math1 gene therapy - GenVec/Novartis; TherAtoH atonal therapy - GenVec/Novartis
Latest Information Update: 20 May 2014
At a glance
- Originator Baylor College of Medicine
- Developer GenVec; Novartis
- Class Gene therapies
- Mechanism of Action Intercellular signalling peptide and protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ear disorders